Switch theme
Sign up to access all valuation multiples
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is KSI-301, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD.
2009
109
LTM Revenue n/a
LTM EBITDA -$189M
$17.3M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Kodiak Sciences has a last 12-month revenue of n/a and a last 12-month EBITDA of -$189M.
In the most recent fiscal year, Kodiak Sciences achieved revenue of n/a and an EBITDA of -$150M.
Kodiak Sciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Kodiak Sciences valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$235M | -$150M | XXX | XXX | XXX |
| EBITDA Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
| Net Profit | -$334M | -$260M | XXX | XXX | XXX |
| Net Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Kodiak Sciences's stock price is $2.
Kodiak Sciences has current market cap of $115M, and EV of $17.3M.
See Kodiak Sciences trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $17.3M | $115M | XXX | XXX | XXX | XXX | $-3.45 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Kodiak Sciences has market cap of $115M and EV of $17.3M.
Kodiak Sciences's trades at n/a LTM EV/Revenue multiple, and -0.1x LTM EBITDA.
Analysts estimate Kodiak Sciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Kodiak Sciences and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $17.3M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | -0.1x | XXX | XXX | XXX |
| P/E | -0.7x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -0.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpKodiak Sciences's NTM/LTM revenue growth is n/a
Kodiak Sciences's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $1.7M for the same period.
Over next 12 months, Kodiak Sciences's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Kodiak Sciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Kodiak Sciences and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | -36% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.7M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Kodiak Sciences acquired XXX companies to date.
Last acquisition by Kodiak Sciences was XXXXXXXX, XXXXX XXXXX XXXXXX . Kodiak Sciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Kodiak Sciences founded? | Kodiak Sciences was founded in 2009. |
| Where is Kodiak Sciences headquartered? | Kodiak Sciences is headquartered in United States of America. |
| How many employees does Kodiak Sciences have? | As of today, Kodiak Sciences has 109 employees. |
| Who is the CEO of Kodiak Sciences? | Kodiak Sciences's CEO is Dr. Victor Perlroth, M.D.. |
| Is Kodiak Sciences publicy listed? | Yes, Kodiak Sciences is a public company listed on NAS. |
| What is the stock symbol of Kodiak Sciences? | Kodiak Sciences trades under KOD ticker. |
| When did Kodiak Sciences go public? | Kodiak Sciences went public in 2018. |
| Who are competitors of Kodiak Sciences? | Similar companies to Kodiak Sciences include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Kodiak Sciences? | Kodiak Sciences's current market cap is $115M |
| What is the current EBITDA of Kodiak Sciences? | Kodiak Sciences's last 12-month EBITDA is -$189M. |
| What is the current EV/EBITDA multiple of Kodiak Sciences? | Current EBITDA multiple of Kodiak Sciences is -0.1x. |
| Is Kodiak Sciences profitable? | Yes, Kodiak Sciences is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
